Skip to content

The Actual News

Stay informed without the news wearing you out.

Breast Cancer Can Outsmart Treatment. Scientists May Know How to Stop It

Breast Cancer Can Outsmart Treatment. Scientists May Know How to Stop It

Summary

Researchers at MD Anderson identified PARP and SHP2 as potential targets in breast cancer cells that became resistant to MCL1 inhibitors. In mouse models, blocking both targets led to near-complete regression of BRCA1-deficient tumors, but the results have not yet been shown to apply to people.

Key Facts

  • The researchers used the computational method TargetScore to track changes in proteins and signaling networks as cancer cells adapted to treatment.
  • They studied breast cancer cells exposed to MCL1 inhibitors for up to four months.
  • Resistant cells showed increased reliance on pathways tied to cell growth and DNA repair.
  • Researchers tested combined PARP and SHP2 inhibition across several breast cancer cell models and found additive to synergistic effects.
  • In mice with BRCA1-deficient breast tumors, the combination produced near-complete tumor regression by day 35.
  • Three of nine mice remained in complete remission beyond 150 days, and median survival in the combination group was 239 days during a 400-day follow-up.
  • The findings come from preclinical models and are not yet directly applicable to human patients.
Read the Full Article

This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.

The week's biggest stories, one calm email every Monday.